MICHÁLEK, Jaroslav, Rene MOSTER, Ladislav LUKAC, Kenneth PROEFROCK, Miron PETRASOVIC, Jakub RYBAR, Martina CAPKOVA, Ales CHALOUPKA, Adas DARINSKAS, Jaroslav sr. MICHALEK, Jan KŘÍSTEK, Jan TRAVNIK, Petr JABANDŽIEV, Marek CIBULKA, Michal HOLEK, Michal JURÍK, Josef SKOPALÍK, Zlatuše KŘÍSTKOVÁ and Zuzana DUDÁŠOVÁ. Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis. Cell Transplantation. Putnam Valley: Cognizant Communication Corporation, 2015. ISSN 0963-6897. Available from: https://dx.doi.org/10.3727/096368915X686760.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Autologous adipose tissue-derived stromal vascular fraction cells application in patients with osteoarthritis
Authors MICHÁLEK, Jaroslav, Rene MOSTER, Ladislav LUKAC, Kenneth PROEFROCK, Miron PETRASOVIC, Jakub RYBAR, Martina CAPKOVA, Ales CHALOUPKA, Adas DARINSKAS, Jaroslav sr. MICHALEK, Jan KŘÍSTEK, Jan TRAVNIK, Petr JABANDŽIEV, Marek CIBULKA, Michal HOLEK, Michal JURÍK, Josef SKOPALÍK, Zlatuše KŘÍSTKOVÁ and Zuzana DUDÁŠOVÁ.
Edition Cell Transplantation, Putnam Valley, Cognizant Communication Corporation, 2015, 0963-6897.
Other information
Type of outcome Article in a journal
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.427
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3727/096368915X686760
Keywords in English stromal vascular fraction; cells; adipose tissue; connective tissue; osteoarthritis; therapy
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 20/7/2015 16:54.
Abstract
Stromal vascular fraction (SVF), containing large amount of stem cells and other regenerative cells, can be easily obtained from loose connective tissue that is associated with adipose tissue. Here we evaluated safety and clinical efficacy of freshly isolated autologous SVF cells in a case control study in patients with grade 2-4 degenerative osteoarthritis (OA). A total of 1128 patients underwent standard liposuction under local anesthesia and SVF cells were isolated and prepared for application into 1-4 large joints. A total of 1856 joints, mainly knee and hip joints, were treated with a single dose of SVF cells. 1114 patients were followed for 12.1-54.3 months (median 17.2 months) for safety and efficacy. Modified KOOS/HOOS Clinical Score was used to evaluate clinical effect and was based on pain, non-steroid analgesic usage, limping, extent of joint movement, and stiffness evaluation before and at 3, 6, and 12 months after the treatment. No serious side effects, systemic infection or cancer was associated with SVF cell therapy. Most patients gradually improved 3-12 months after the treatment. At least 75% Score improvement was noticed in 63% of patients and at least 50% Score improvement was documented in 91% of patients 12 months after SVF cell therapy. Obesity and higher grade of OA were associated with slower healing. In conclusion, here we report a novel and promising treatment approach for patients with degenerative OA that is safe, cost-effective, and relying only on autologous cells.
Links
EE2.3.20.0012, research and development projectName: Mezinárodní konsorcium pro buněčnou terapii a imunoterapii
LM2011017, research and development projectName: Advanced Cell Immunotherapy Unit - ACIU
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 25/5/2024 03:08